Documentaries, videos and podcasts
May 27, 2021
Biorasi, a leading global full-service contract research organization, is proud to announce the appointment of Alex A. Adjei, MD, PhD, FACP to the position of Scientific Advisory Board member.
May 21, 2021
RYBREVANTTM (amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations - read this article along with other careers information, tips and advice on BioSpace
Janssen Pharmaceutical Companies of Johnson & Johnson
May 21, 2021
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has granted the...
National Comprehensive Cancer Network
September 17, 2019
PLYMOUTH MEETING, Pa., Sept. 17, 2019 /PRNewswire/ -- New research in the September 2019 issue of JNCCN--Journal of the National Comprehensive Cancer Network...
August 27, 2019
SANTA MONICA, Calif., Aug. 27, 2019 /PRNewswire/ -- Nearly 46 percent of medical school graduates are women, yet women physicians remain underrepresented in...
NEW YORK, Feb. 18, 2019 /PRNewswire/ -- This report analyzes the worldwide markets for Nuclear Medicine Imaging Equipment in US$ Thousand by the following...
January 8, 2019
AstraZeneca is announcing organisational changes to support continued scientific innovation and commercial success in the main therapy areas as the Company enters a new phase in its strategic development. Included in the changes will be the arrival at AstraZeneca of the world-renowned oncology scientist, José Baselga, as well as the creation of: , , , , , , • Therapy area-focused Research and Development units that are responsible for discovery through to late-stage development - one for BioPh...
December 7, 2018
AstraZeneca and MedImmune, its global biologics research and development arm, announced overall survival (OS) results for the Phase III EAGLE trial. EAGLE is a randomised, open-label, multi-centre trial evaluating Imfinzi (durvalumab) monotherapy or Imfinzi in combination with tremelimumab, an anti-CTLA4 antibody, versus standard-of-care (SoC) chemotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who experienced disease progression follow...
Be the first contributor by making edits